Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders

Internal Medicine
Shinya WatanabeTakafumi Suda

Abstract

Slow responders to pegylated interferon (Peg-IFN) and ribavirin (RBV) among patients infected with hepatitis C virus (HCV) genotype 1 may benefit from an extended treatment course. The aim of this study was to determine the efficacy of persistent negative serum HCV RNA over 96 weeks during long-term Peg-IFN monotherapy following 72 weeks of combination therapy. A total of 46 HCV genotype 1-infected slow responders were treated for 72 weeks with Peg-IFN and RBV combination therapy alone (n=25) or additional long-term biweekly treatment with 90 μg of Peg-IFN-α2a (n=21). The criterion for the completion of long-term Peg-IFN monotherapy was defined as the attainment of constantly negative HCV RNA in the serum over 96 weeks during IFN treatment. The patients with sustained negative serum HCV RNA during 96 weeks of IFN treatment had a higher rate of sustained virological response (SVR) than those without (81 vs. 40%, p=0.012). A multivariate analysis identified sustained negativity of serum HCV RNA over 96 weeks of IFN treatment to be a predictive factor for SVR. In the present study, sustained negative serum HCV RNA over 96 weeks during long-term Peg-IFN monotherapy following 72 weeks of combination therapy of Peg-IFN and RBV result...Continue Reading

References

Jun 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·V J DesmetP J Scheuer
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Dec 10, 2003·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Hideyuki NomuraHiromi Ishibashi
Mar 5, 2004·Annals of Internal Medicine·Stephanos J HadziyannisUNKNOWN PEGASYS International Study Group
Nov 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Brian L PearlmanSophia Saifee
Nov 17, 2009·Gastroenterology·Peter FerenciUNKNOWN Austrian Hepatitis Study Group
Aug 5, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Maria ButiUNKNOWN SUCCESS Study Investigators
Jan 11, 2012·Liver International : Official Journal of the International Association for the Study of the Liver·Philippe Halfon, Christoph Sarrazin
Dec 4, 2012·Best Practice & Research. Clinical Gastroenterology·Peter Ferenci
Mar 8, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Alessio Aghemo, Raffaele De Francesco
May 4, 2013·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Tomoyuki TakashimaShuhei Nishiguchi
Jul 3, 2013·Nature Reviews. Gastroenterology & Hepatology·Jennifer J KiserGregory T Everson
Jan 1, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Raymond SchinaziTarik Asselah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.